| Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial C Male, AWA Lensing, JS Palumbo, R Kumar, I Nurmeev, K Hege, ... The Lancet Haematology 7 (1), e18-e27, 2020 | 267 | 2020 |
| Patient-centered eHealth interventions for children, adolescents, and adults with sickle cell disease: systematic review SM Badawy, RM Cronin, J Hankins, L Crosby, M DeBaun, AA Thompson, ... Journal of medical Internet research 20 (7), e10940, 2018 | 165 | 2018 |
| Sickle cell disease complications: prevalence and resource utilization N Shah, M Bhor, L Xie, J Paulose, H Yuce PloS one 14 (7), e0214355, 2019 | 106 | 2019 |
| Patients welcome the sickle cell disease mobile application to record symptoms via technology (SMART) N Shah, J Jonassaint, L De Castro Hemoglobin 38 (2), 99-103, 2014 | 99 | 2014 |
| Usability and feasibility of an mHealth intervention for monitoring and managing pain symptoms in sickle cell disease: the Sickle Cell Disease Mobile Application to Record … CR Jonassaint, N Shah, J Jonassaint, L De Castro Hemoglobin 39 (3), 162-168, 2015 | 83 | 2015 |
| Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings NA Goldenberg, T Abshire, PJ Blatchford, LZ Fenton, JL Halperin, ... Journal of Thrombosis and Haemostasis 13 (9), 1597-1605, 2015 | 81 | 2015 |
| Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study N Shah, M Bhor, L Xie, R Halloway, S Arcona, J Paulose, H Yuce Health and Quality of Life Outcomes 17, 1-11, 2019 | 72 | 2019 |
| The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease LD DiMartino, AA Baumann, LL Hsu, J Kanter, VR Gordeuk, J Glassberg, ... American journal of hematology 93 (12), E391, 2018 | 68 | 2018 |
| Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the … NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca, JF Casella, ... Jama 327 (2), 129-137, 2022 | 66 | 2022 |
| Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation G Young, AWA Lensing, P Monagle, C Male, K Thelen, S Willmann, ... Journal of Thrombosis and Haemostasis 18 (7), 1672-1685, 2020 | 66 | 2020 |
| Transition to adult care in sickle cell disease: a longitudinal study of clinical characteristics and disease severity M Kayle, SL Docherty, R Sloane, P Tanabe, G Maslow, W Pan, N Shah Pediatric blood & cancer 66 (1), e27463, 2019 | 56 | 2019 |
| Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: the emergency department providers’ perspective RV Masese, D Bulgin, C Douglas, N Shah, P Tanabe PLoS One 14 (5), e0216414, 2019 | 54 | 2019 |
| Use of mobile health apps and wearable technology to assess changes and predict pain during treatment of acute pain in sickle cell disease: feasibility study A Johnson, F Yang, S Gollarahalli, T Banerjee, D Abrams, J Jonassaint, ... JMIR mHealth and uHealth 7 (12), e13671, 2019 | 51 | 2019 |
| Characterization of the hypercoagulable state in patients with sickle cell disease N Shah, C Thornburg, MJ Telen, TL Ortel Thrombosis research 130 (5), e241-e245, 2012 | 51 | 2012 |
| Mobile health intervention for youth with sickle cell disease: Impact on adherence, disease knowledge, and quality of life LM Anderson, S Leonard, J Jonassaint, J Lunyera, M Bonner, N Shah Pediatric blood & cancer 65 (8), e27081, 2018 | 50 | 2018 |
| Pregnancy outcomes with hydroxyurea use in women with sickle cell disease BL Kroner, JS Hankins, N Pugh, A Kutlar, AA King, NR Shah, J Kanter, ... American journal of hematology 97 (5), 603-612, 2022 | 49 | 2022 |
| Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: a retrospective claims study N Shah, M Bhor, L Xie, J Paulose, H Yuce Journal of health economics and outcomes research 7 (1), 52, 2020 | 45 | 2020 |
| Improving pain management in patients with sickle cell disease from physiological measures using machine learning techniques F Yang, T Banerjee, K Narine, N Shah Smart Health 7, 48-59, 2018 | 45 | 2018 |
| Patient‐reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium MR Knisely, N Pugh, B Kroner, R Masese, V Gordeuk, AA King, SM Smith, ... American journal of hematology 95 (9), 1066-1074, 2020 | 43 | 2020 |
| Advances in iron chelation therapy: transitioning to a new oral formulation NR Shah Drugs in context 6, 212502, 2017 | 41 | 2017 |